Abstract
Chronic hepatitis C infection is a leading cause of morbidity and mortality worldwide, with hepatitis C related cirrhosis being the most common indication for transplant and a major cause for the increase in hepatocellular carcinoma worldwide. Treatment for hepatitis C has consisted of nonspecific immunomodulatory therapies that stimulate the immune system and inhibit hepatitis C replication. Pegylated (peg-)interferon and ribavirin have been the standard of care with an overall sustained response rate of 40-50% in patients with genotype 1 infection, and 80% in genotype 2 or 3. Recently, direct-acting antiviral agents, including boceprevir, have demonstrated improved sustained response rates in patients with genotype 1 infection when given in combination with interferon and ribavirin. Boceprevir is a structurally novel hepatitis C virus (HCV) nonstructural 3 (NS3) protease inhibitor that has demonstrated robust antiviral activity in HCV replicons. Clinically, in phase II and III trials, boceprevir 800 mg three times daily with peginterferon and ribavirin has led to improved sustained response rates in genotype 1 infection treatment-naive patients, relapsers, partial responders, and null responders. Phase II data have demonstrat...Continue Reading
References
Jul 3, 1999·Science·V LohmannR Bartenschlager
Jun 22, 2000·The Journal of General Virology·R Bartenschlager, V Lohmann
Oct 26, 2000·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·T PoynardJ Albrecht
Jul 7, 2001·The New England Journal of Medicine·G M Lauer, B D Walker
Nov 5, 2002·Nature Reviews. Drug Discovery·Ralf Bartenschlager
Nov 28, 2002·Gastroenterology
May 28, 2004·The New England Journal of Medicine·Andrew J MuirUNKNOWN Atlantic Coast Hepatitis Treatment Group
Feb 24, 2006·Antimicrobial Agents and Chemotherapy·B A MalcolmF G Njoroge
Aug 8, 2006·Gastroenterology·Hari S ConjeevaramUNKNOWN Virahep-C Study Group
Dec 8, 2006·The New England Journal of Medicine·Jay H Hoofnagle, Leonard B Seeff
Apr 6, 2007·Gastroenterology·Christoph SarrazinStefan Zeuzem
Jun 7, 2007·World Journal of Gastroenterology : WJG·Miriam J Alter
Jun 16, 2007·Gastroenterology·Hashem B El-Serag, K Lenhard Rudolph
Jul 13, 2007·The New England Journal of Medicine·Mitchell L ShiffmanUNKNOWN ACCELERATE Investigators
Oct 22, 2008·Antimicrobial Agents and Chemotherapy·Mike FlintAnita Y M Howe
Jan 16, 2009·The New England Journal of Medicine·Maribel Rodriguez-TorresUNKNOWN Latino Study Group
Oct 29, 2009·Gastroenterology·Gary L DavisLinda W Jennings
Nov 17, 2009·Gastroenterology·Peter FerenciUNKNOWN Austrian Hepatitis Study Group
Mar 3, 2010·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Moises DiagoDavid R Nelson
Apr 20, 2010·Gastroenterology·Alexander J ThompsonJohn G McHutchison
Aug 10, 2010·Lancet·Paul Y KwoUNKNOWN SPRINT-1 investigators
Aug 21, 2010·Gastroenterology·Mark S SulkowskiUNKNOWN IDEAL Study Team
Oct 19, 2010·Lancet·Edward J GanePatrick F Smith
Apr 1, 2011·The New England Journal of Medicine·Fred PoordadUNKNOWN SPRINT-2 Investigators
Citations
Jan 28, 2014·Antiviral Research·Weiwei XueXiaojun Yao
Feb 24, 2016·Acta Pharmaceutica Sinica. B·Xingquan Zhang
Aug 11, 2015·Japanese Journal of Infectious Diseases·Dadan Ramadhan ApriyantoHak Hotta
Sep 24, 2016·Expert Opinion on Drug Safety·Mohamed El KassasGamal Esmat
Jun 27, 2014·Journal of Virology·Tinashe B RuwonaMansun Law
Sep 10, 2014·Molecular Biology Reports·H Y LanW Yin